MariTide

Maridebart cafraglutide
Clinical data
Other names	AMG 133
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2760218-55-9;
UNII	Z24U3U73HN;

MariTide, also known as maridebart cafraglutide^[1] (developmental name AMG 133), is an investigational drug developed by Amgen for the treatment of obesity. It is an agonist of the GLP-1 receptor (GLP-1R) and an antagonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR). Namely, MariTide consists of a monoclonal antibody against GIPR conjugated to two peptidic GLP-1R agonist molecules via amino acid linkers.^[2] In a preliminary trial, AMG 133 resulted in a 14.5 percent weight loss after 12 weeks at the highest dose tested.^[3]^[4]^[5]

References

^ Beasley, Deena (2024-02-06). "Amgen taking different path to weight loss windfall". Reuters. Retrieved 2024-03-06.
^ Véniant, Murielle M.; Lu, Shu-Chen; Atangan, Larissa; Komorowski, Renee; Stanislaus, Shanaka; Cheng, Yuan; Wu, Bin; Falsey, James R.; Hager, Todd; Thomas, Veena A.; Ambhaikar, Malhar; Sharpsten, Lucie; Zhu, Yineng; Kurra, Vamsi; Jeswani, Rohini (2024-02-05). "A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings". Nature Metabolism. 6 (2): 290–303. doi:10.1038/s42255-023-00966-w. ISSN 2522-5812. PMC 10896721. PMID 38316982.
^ Hammoud, Rola; Drucker, Daniel J. (April 2023). "Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1". Nature Reviews Endocrinology. 19 (4): 201–216. doi:10.1038/s41574-022-00783-3. ISSN 1759-5037.
^ Jepsen, Mathies M.; Christensen, Mikkel B. (3 July 2021). "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity". Expert Opinion on Emerging Drugs. 26 (3): 231–243. doi:10.1080/14728214.2021.1947240.
^ Bailey, Clifford J.; Flatt, Peter R.; Conlon, J. Michael (1 March 2023). "An update on peptide-based therapies for type 2 diabetes and obesity". Peptides. 161: 170939. doi:10.1016/j.peptides.2023.170939. ISSN 0196-9781.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Beasley_2024_f568-1] Beasley, Deena (2024-02-06). "Amgen taking different path to weight loss windfall". Reuters. Retrieved 2024-03-06.

[2] Véniant, Murielle M.; Lu, Shu-Chen; Atangan, Larissa; Komorowski, Renee; Stanislaus, Shanaka; Cheng, Yuan; Wu, Bin; Falsey, James R.; Hager, Todd; Thomas, Veena A.; Ambhaikar, Malhar; Sharpsten, Lucie; Zhu, Yineng; Kurra, Vamsi; Jeswani, Rohini (2024-02-05). "A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings". Nature Metabolism. 6 (2): 290–303. doi:10.1038/s42255-023-00966-w. ISSN 2522-5812. PMC 10896721. PMID 38316982.

[3] Hammoud, Rola; Drucker, Daniel J. (April 2023). "Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1". Nature Reviews Endocrinology. 19 (4): 201–216. doi:10.1038/s41574-022-00783-3. ISSN 1759-5037.

[4] Jepsen, Mathies M.; Christensen, Mikkel B. (3 July 2021). "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity". Expert Opinion on Emerging Drugs. 26 (3): 231–243. doi:10.1080/14728214.2021.1947240.

[5] Bailey, Clifford J.; Flatt, Peter R.; Conlon, J. Michael (1 March 2023). "An update on peptide-based therapies for type 2 diabetes and obesity". Peptides. 161: 170939. doi:10.1016/j.peptides.2023.170939. ISSN 0196-9781.

[1]